I had a look at the clinical trial details and it looks like we won't be getting a readout for 002 stage I. Instead the DMC will simply select the dose based on the signals they're seeing in the data, which I presume will be based on the primary endpoint we've selected. I also assume the DMC will also factor into the equation the additional 468 patients to be recruited in stage II when they determine if they expect to see a separation between the treated group and placebo. The primary endpoint appears easy for PAR to achieve, but we also need to keep in mind the treatment also needs to be clinically meaningful.
- Forums
- ASX - By Stock
- Ann: PAR Reports Phase 3 Clinical Trial Update
I had a look at the clinical trial details and it looks like we...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M |
Open | High | Low | Value | Volume |
26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 11571 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 0.245 |
8 | 120363 | 0.240 |
5 | 126753 | 0.235 |
5 | 146782 | 0.230 |
2 | 53000 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 11571 | 1 |
0.260 | 15236 | 1 |
0.265 | 59987 | 2 |
0.270 | 10000 | 1 |
0.275 | 16347 | 3 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online